Phase II study of ecteinascidin 743 in heavily pretreated patients with recurrent osteosarcoma

BACKGROUND Recurrent osteosarcoma is a drug‐resistant disease with a dismal prognosis. The objective of this Phase II study was to evaluate the activity of ecteinascidin 743 (ET‐743) as a salvage therapy in these patients. METHODS Patients with recurrent osteosarcoma who had received standard chemot...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Cancer 2003-08, Vol.98 (4), p.832-840
Hauptverfasser:	Laverdiere, Caroline, Kolb, E. Anders, Supko, Jeffrey G., Gorlick, Richard, Meyers, Paul A., Maki, Robert G., Wexler, Leonard, Demetri, George D., Healey, John H., Huvos, Andrew G., Goorin, Allen M., Bagatell, Rochelle, Ruiz‐Casado, Ana, Guzman, Cecilia, Jimeno, Jose, Harmon, David
Format:	Artikel
Sprache:	eng
Schlagworte:	Adolescent Adult Aged Antineoplastic agents Antineoplastic Agents, Alkylating - adverse effects Antineoplastic Agents, Alkylating - pharmacokinetics Antineoplastic Agents, Alkylating - therapeutic use Antineoplastic Combined Chemotherapy Protocols - therapeutic use Biological and medical sciences Bone Neoplasms - drug therapy Bone Neoplasms - pathology Chemotherapy Child Dioxoles - adverse effects Dioxoles - pharmacokinetics Dioxoles - therapeutic use ecteinascidin‐743 (ET‐743) Female Humans Isoquinolines - adverse effects Isoquinolines - pharmacokinetics Isoquinolines - therapeutic use Male Medical sciences Middle Aged osteosarcoma Osteosarcoma - drug therapy Osteosarcoma - secondary Pharmacology. Drug treatments Phase II study Salvage Therapy sarcoma Tetrahydroisoquinolines
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!